sj-docx-1-tah-10.1177_20406207231199837 – Supplemental material for Alterations of erythropoiesis in Covid-19 patients: prevalence of positive Coombs tests and iron metabolism

Supplemental material, sj-docx-1-tah-10.1177_20406207231199837 for Alterations of erythropoiesis in Covid-19 patients: prevalence of positive Coombs tests and iron metabolism by Léa Schmitz, Michelle Pirotte, Alizée Lebeau, Marie Ernst, Marianne Fillet, Anais Devey, Justine Schmitt, Gaël Cobraiville, Marilène Binsfeld, Stéphanie Gofflot, Yves Beguin and Gaëlle Vertenoeil in Therapeutic Advances in Hematology</p

Table_1_Progressive fibrosing interstitial lung disease in rheumatoid arthritis: A retrospective study.DOCX

Background and objectiveRheumatoid arthritis associated-interstitial lung disease (RA-ILD) is the most common pulmonary manifestation of rheumatoid arthritis (RA) and an important cause of mortality. In patients suffering from interstitial lung diseases (ILD) from different etiologies (including RA-ILD), a significant proportion is exhibiting a fibrotic progression despite immunosuppressive therapies, defined as progressive fibrosing interstitial lung disease (PF-ILD). Here, we report the frequency of RA-ILD and PF-ILD in all RA patients’ cohort at University Hospital of Liège and compare their characteristics and outcomes.MethodsPatients were retrospectively recruited from 2010 to 2020. PF-ILD was defined based on functional, clinical and/or iconographic progression criteria within 24 months despite specific anti-RA treatment.ResultsOut of 1,500 RA patients, about one third had high-resolution computed tomography (HRCT) performed, 89 showed RA-ILD and 48 PF-ILD. RA-ILD patients were significantly older than other RA patients (71 old of median age vs. 65, p ConclusionWe identified a prevalence of PF-ILD of 3% in a general RA population. The PF-ILD cohort did not seem to be different in terms of demographic characteristics and mortality compared to RA-ILD patients who did not exhibit the progressive phenotype yet.</p